The challenge of renal function in heart transplant children

Pediatric Nephrology

Volumn 22, Issue 3, 2007, Pages 333-342

  Di Filippo, Sylvie ^a   Cochat, Pierre ^b   Bozio, André ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Calcineurine inhibitor; Heart transplantation; Nephrotoxicity; Renal dysfunction; TGF 1

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RENIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1;

AREA UNDER THE CURVE; ARTERY DISEASE; CARDIAC GRAFT REJECTION; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOLLOW UP; GENETIC CODE; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART TRANSPLANTATION; HISTOPATHOLOGY; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; KIDNEY BLOOD VESSEL; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION TEST; KIDNEY INJURY; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; UPREGULATION; VASOCONSTRICTION;

CALCINEURIN; CHILD; CHRONIC DISEASE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES;

EID: 34248675212     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0229-9     Document Type: Review

References (90)

1. Phan V, West LJ, Stephens D, Hebert D (2003) Renal complications following heart transplantation in children: A single-center study. Am J Transplant 3:214-218
2. Pradhan M, Leonard MB, Bridges ND, Jabs KL (2002) Decline in renal function following thoracic organ transplantation in children. Am J Transplant 2:652-657
3. Laine J, Jalanko H, Leijala M, Sairanen H, Holmberg C (1997) Kidney function in cyclosporine-treated pediatric heart transplant recipients. J Heart Lung Transplant 16:1217-1224
4. Sigfusson G, Fricker FJ, Bernstein D, Addonizio LJ, Baum D, Hsu DT, Chin C, Miller SA, Boyle GJ, Miller J, Lawrence KS, Douglas JF, Griffith BP, Reitz BA, Michler RE, Rose EA, Webber SA (1997) Long-term survivors of pediatric heart transplantation: A multicenter report of sixty-eight children who have survived longer than five years. J Pediatr 130:862-871
5. Haverich A, Hirt SW, Wagenberth I, Luhmer I, Ziemer G, Kallfelz HC (1992) Thoracic organ transplantation in the paediatric age group: The Hannover experience. Eur J Pediatr 151 Suppl 1:S65-S69
6. Alonso EM (2004) Long-term renal function in pediatric liver and heart recipients. Pediatr Transplant 8:381-385
7. Veillon S, Caillard S, Epailly E, Eisenmann B, Hannedouche T, Moulin B (2002) Chronic renal failure after cardiac transplantation: Predictive factors and influence on mortality-results of a monocenter study in 141 Patients. Transplant Proc 34:2819-2820
8. van Gelder T, Balk AH, Zietse R, Hesse C, Mochtar B, Weimar W (1998) Renal insufficiency after heart transplantation: A case-control study. Nephrol Dial Transplant 13:2322-2326
9. Jayasena SD, Riaz A, Lewis CM, Neild GH, Thompson FD, Woolfson RG (2001) Outcome in patients with end-stage renal disease following heart or heart-lung transplantation receiving peritoneal dialysis. Nephrol Dial Transplant 16:1681-1685
10. Zuckermann A, Klepetko W (2004) Use of cyclosporine in thoracic transplantation. Transplant Proc 36 Suppl 2:331S-336S
11. Rice JE, Shipp AT, Carlin JB, Vidmar SI, Weintraub RG (2002) Late reduction in cyclosporine dosage does not improve renal function in pediatric heart transplant recipients. J Heart Lung Transplant 21:1109-1112
12. Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 34:571-590
13. English RF, Pophal SA, Bacanu SA, Fricker J, Boyle GJ, Ellis D, Harker K, Sutton R, Miller SA, Law YM, Pigula FA, Webber SA (2002) Long-term comparison of tacrolimus and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. Am J Transplant 2:769-773
14. Lindelow B, Bergh CH, Herlitz H, Waagstein F (2000) Predictors and evolution of renal function during 9 years following heart transplantation. J Am Soc Nephrol 11:951-957
15. Di Filippo S, Zeevi A, McDade KK, Boyle GJ, Miller SA, Gandhi SK, Webber SA (2005) Impact of TGF-β1 gene polymorphisms on late renal function in pediatric heart transplantation. Hum Immunol 66:133-139
16. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D (1997) Cyclosporine-associated end-stage nephropathy after cardiac transplantation: Incidence and progression. Transplantation 63:664-668
17. Lewis RM, Verani RR, Vo C, Katz SM, Van Buren CT, Radovancevic B, Kerman RH, Frazier OH, Kahan BD (1994) Evaluation of chronic renal disease in heart transplant recipients: Importance of pretransplantation native kidney histologic evaluation. J Heart Lung Transplant 13:376-380
18. Baran DA, Galin ID, Gass AL (2004) Calcineurin inhibitor-associated early renal insufficiency in cardiac transplant recipients: Risk factors and strategies for prevention and treatment. Am J Cardiovasc Drugs 4:21-29
19. Shihab FS, Bennett WM, Tanner AM, Andoh TF (1997) Mechanisms of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 64:1829-1837
20. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S (2002) Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 62:2257-2263
21. Yamamoto T, Noble NA, Miller DE, Border WA (1994) Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 45:916-927
22. Prashar Y, Khanna A, Sehajpal P, Sharma VK, Suthanthiran M (1995) Stimulation of transforming growth factor-beta 1 transcription by cyclosporine. FEBS Lett 358:109-112
23. Shin GT, Khanna A, Ding R, Sharma VK, Lagman M, Li B, Suthanthiran M (1998) In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation 65:131-138
24. Lacha J, Hubacek JA, Potmesil P, Viklicky O, Malek I, Vitko S (2001) TGF-beta I gene polymorphism in heart transplant recipients-effect on renal function. Ann Transplant 6:39-43
25. Baan CC, Balk AH, Holweg CT, Van Riemsdijk IC, Maat LP, Vantrimpont PJ, Niesters HG, Weimar W (2000) Renal failure after clinical heart transplantation is associated with the TGF-beta 1 codon 10 gene polymorphism. J Heart Lung Transplant 19:866-872
26. Woolfson RG, Neild GH (1997) Cyclosporine nephrotoxicity following cardiac transplantation. Nephrol Dial Transplant 12:2054-2056
27. Zheng HX, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP, Webber S, Ristich J, Dauber J, Iacono A, Grgurich W, Zaldonis D, McDade K, Zhang J, Burckart GJ (2004) Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 44:135-140
28. Zheng HX, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, Burckart GJ (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3:477-483
29. Boucek MM, Edwards LB, Keck BM, Trulock EP, Taylor DO, Hertz MI (2004) Registry for the International society for heart and lung transplantation: Seventh official pediatric report-2004. J Heart Lung Transplant 23:933-947
30. Ventura HO, Malik FS, Mehra MR, Stapleton DD, Smart FW (1997) Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 12:375-381
31. Perloff JK, Latta H, Barsotti P (2000) Pathogenesis of the glomerular abnormality in cyanotic congenital heart disease. Am J Cardiol 86:1198-1204
32. Awad H, el-Safty I, Abdel-Gawad M, el-Said S (2003) Glomerular and tubular dysfunction in children with congenital cyanotic heart disease: effect of palliative surgery. Am J Med Sci 325:110-114
33. Ishani A, Erturk S, Hertz MI, Matas AJ, Savik K, Rosenberg ME (2002) Predictors of renal function following lung or heart-lung transplantation. Kidney Int 61:2228-2234
34. Hornung TS, de Goede CG, O'Brien C, Moghal NE, Dark JH, O'Sullivan FP (2001) Renal function after pediatric cardiac transplantation: The effect of early cyclosporin dosage. Pediatrics 107:1346-1350
35. Dello Strologo L, Parisi F, Legato A, Pontesilli C, Pastore A, Rava L, Tozzi AE, Rizzoni F (2006) Long-term renal function in heart transplant children on cyclosporine treatment. Pediatr Nephrol 21:561-565
36. Camara NO, Matos AC, Rodrigues DA, Pereira AB, Pacheco-Silva A (2001) Early detection of heart transplant patients with increased risk of ciclosporin nephrotoxicity. Lancet 357:856-857
37. Asante-Korang A, Boyle GJ, Webber SA, Miller SA, Fricker FJ (1996) Experience of FK506 immune suppression in pediatric heart transplantation: A study of long-term adverse effects. J Heart Lung Transplant 15:415-422
38. Swenson JM, Fricker FJ, Armitage JM (1995) Immunosuppression switch in pediatric heart transplant recipients: Cyclosporine to FK 506. J Am Coll Cardiol 25:1183-1188
39. Bennett WM, Hosenpud J, Pantley G, Cobanoglu A, Starr A, Norman DJ (1989) Renal consequences of a low dose cyclosporine triple therapy regimen in cardiac transplantation. Transplant Proc 21:2479-2480
40. Dipchand AI, Benson L, McCrindle BW, Coles J, West L (2001) Mycophenolate mofetil in pediatric heart transplant recipients: A single-center experience. Pediatr Transplant 5:112-118
41. Kamar N, Allard J, Ader JL, Rostaing L (2004) Cyclosporine-A-based immunosuppression and renal functional reserve in organ-transplant patients. Transplant Proc 36:248S-250S
42. Sindhi R (2003) Sirolimus in pediatric transplant recipients. Transplant Proc 35:113S-114S
43. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P; RAD B253 Study Group (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349:847-858
44. Tedoriya T, Keogh AM, Kusano K, Savdie E, Hayward C, Spratt PM, Wilson M, Macdonald PS (2002) Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J Heart Lung Transplant 21:976-982
45. Baryalei M, Zenker D, Pieske B, Tondo K, Dalichau H, Aleksic I (2003) Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 35:1539-1542
46. Sanchez V, Delgado JF, Morales JM, Tello R, Gomez MA, Escribano P, de la Camara AG, de la Calzada CS (2004) Chronic cyclosporine-induced nephrotoxicity in heart transplant patients: Long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 36:2823-2825
47. Aleksic I, Baryalei M, Busch T, Pieske B, Schorn B, Strauch J, Sirbu H, Dalichau H (2000) Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 69:1586-1590
48. Angermann CE, Stork S, Costard-Jackle A, Dengler TJ, Siebert U, Tenderich G, Rahmel A, Schwarz ER, Nagele H, Wagner FM, Haaff B, Pethig K (2004) Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients: The IMPROVED multi-centre study. Eur Heart J 25:1626-1634
49. Boyer O, Le Bidois J, Dechaux M, Gubler MC, Niaudet P (2005) Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 79:1405-1410
50. Reich DJ, Clavien PA, Hodge EE; MMF Renal Dysfunction after Liver Transplantation Working Group (2005) Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: Randomized, prospective, multicenter pilot study results. Transplantation 80:18-25
51. Beckebaum S, Cicinnati VR, Klein CG, Brokalaki E, Yu Z, Malago M, Frilling A, Gerken G, Broelsch CE (2004) Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: Preliminary results of an open prospective study. Transplant Proc 36:2671-2674
52. Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roth D, Kupin W, Nicolas M, Ruiz P, Rosen A, Miller J (2004) A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 77:252-258
53. Filler G, Gellermann J, Zimmering M, Mai I (2000) Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. Transplant Int 13:201-206
54. De Sevaux RG, Gregoor PJ, Hene RJ, Hoitsma AJ, Vos P, Weimar W, Van Gelder T, Hilbrands LB (2001) A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. J Am Soc Nephrol 12:1750-1757
55. Starling RC, Hare JM, Hauptman P, McCurry KR, Mayer HW, Kovarik JM, Schmidli H (2004) Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 4:2126-2131
56. Zucker MJ, Baran DA, Arroyo LH, Goldstein DJ, Neacy C, Mele L, Weinberg AD, Prendergast TW, Ribner HS (2005) De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: A one-year follow-up analysis. Transplant Proc 37:2231-2239
57. Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S; Prograf Study Group (2005) A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 80:303-309
58. van Hooff JP, Squifflet JP, Wlodarczyk Z, Vanrenterghem Y, Paczek L (2003) A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 75:1934-1939
59. Legendre C, Campistol JM, Squifflet JP, Burke JT; Sirolimus European Renal Transplant Study Group (2003) Cardiovascular risk factors of sirolimus compared with cyclosporine: Early experience from two randomized trials in renal transplantation. Transplant Proc 35:151S-153S
60. Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S; Prograf Study Group (2003) Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months. Transplantation 75:1213-1220
61. Saunders RN, Bicknell GR, Nicholson ML (2003) The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 75:772-780
62. Hoyer PF, Ettenger R, Kovarik JM, Webb NJ, Lemire J, Mentser M, Mahan J, Loirat C, Niaudet P, VanDamme-Lombaerts R, Offner G, Wehr S, Moeller V, Mayer H; Everolimus Pediatric Study Group (2003) Everolimus in pediatric de nova renal transplant patients. Transplantation 75:2082-2085
63. Groetzner J, Meiser B, Landwehr P, Buehse L, Mueller M, Kaczmarek I, Vogeser M, Daebritz S, Ueberfuhr P, Reichart B (2004) Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 77:568-574
64. Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J (2001) Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 357:587-591
65. Dudley C, Pohanka E, Riad H, Dedochova J, Wijngaard P, Sutter C, Silva HT Jr; Mycophenolate Mofetil Creeping Creatinine Study Group (2005) Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 79:466-475
66. Suwelack B, Gerhardt U, Hohage H (2004) Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 4:655-662
67. Abramowicz D, Del Carmen Rial M, Vitko S, del Castillo D, Manas D, Lao M, Gafner N, Wijngaard P; Cyclosporine Withdrawal Study Group (2005) Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 16:2234-2240
68. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W, Hilbrands LB, van Gelder T (2002) Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J Am Soc Nephrol 13:1365-1373
69. Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyo JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF; Rapamune Maintenance Regimen Study Group (2005) Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 18:22-28
70. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP; Sirolimus Renal Function Study Group (2002) Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 74:1560-1567
71. Ruiz JC, Campistol JM, Mota A, Prats D, Gutierrez JA, Castro A, Garcia J, Morales JM, Grynio JM, Gomez JM, Arias M (2003) Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplant Proc 35:1669-1670
72. Grinyo JM, Campistol JM, Paul J, Garcia-Martinez J, Morales JM, Prats D, Arias M, Brunet M, Cabrera J, Granados E (2004) Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 4:1308-1314
73. Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto M, Campistol JM, Hutchison B, Burke JT, Yilmaz S, Hayry P, Neylan JF; Rapamune Maintenance Regimen Trial (2004) Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4:953-961
74. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF; Rapamune Maintenance Regimen Trial (2004) Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15:809-817
75. Grinyo JM, Gil-Vernet S, Cruzado JM, Caldes A, Riera L, Seron D, Rama I, Torras J (2003) Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: Results after 5 years. Transplant Int 16:820-827
76. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B (2001) Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71:1282-1287
77. Meiser B, Reichart B, Adamidis I, Uberfuhr P, Kaczmarek I (2005) First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 5:827-831
78. Hamdy AF, El-Agroudy AE, Bakr MA, Mostafa A, El-Baz M, El-Shahawy el-M, Ghoneim MA (2005) Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 5:2531-2538
79. Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H, Hammond JA, Whisenant T, Lanigan CM, Head SR, Salomon DR (2004) De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 4:1776-1785
80. Deeb GM, Kolff J, McClurken JB, Dunn J, Balsara R, Ochs R, Badellino M, Hollander T, Eldridge C, Clancey M (1987) Antithymocyte gamma globulin, low-dosage cyclosporine, and tapering steroids as an immunosuppressive regimen to avoid early kidney failure in heart transplantation. J Heart Transplant 6:79-83
81. Heffron TG, Pillen T, Smallwood GA, Welch D, Oakley B, Romero R (2003) Pediatric liver transplantation with daclizumab induction. Transplantation 75:2040-2043
82. Belitsky P, Dunn S, Johnston A, Levy G (2000) Impact of absorption profiling on efficacy and safety of cyclosporine therapy in transplant recipients. Clin Pharmacokinet 39:117-125
83. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R (1998) Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 12:243-249
84. Schuetz M, Einecke G, Mai I, Neumayer HH, Glander P, Waiser J, Fritsche L, Budde K (2005) Problems of cyclosporine absorption profiling using C2-monitoring. Eur J Med Res 10:175-178
85. Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB, Angelini A, Alaibac M, Bontorin M, Calzolari D, Peserico A, Thiene G, Iliceto S, Gerosa G (2005) C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transplant Int 18:116-124
86. Trompeter R, Fitzpatrick M, Hutchinson C, Johnston AN (2003) Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant 7:282-288
87. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P (1998) Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 66:1621-1627
88. Baraldo M, Pea F, Poz D, Albanese M.C, Livi U, Furlanut M (2001) Cyclosporine dose fractioning might affect renal function in stable heart transplanted patients. Transplant Proc 33:3151-3153
89. Sun BK, Li C, Lim SW, Choi BS, Lee SH, Kim IS, Kim YS, Bang BK, Yang CW (2005) Blockade of angiotensin II with losartan attenuates transforming growth factor-beta 1 inducible Gene-h3 (betaig-h3) expression in a model of chronic cyclosporine nephrotoxicity. Nephron Exp Nephrol 99:e9-e16
90. Khanna AK, Cairns VR, Becker CG, Hosenpud JD (1999) Transforming growth factor (TGF)-beta 1 mimics and anti-TGF-β1 antibody abrogates the in vivo effects of cyclosporine: Demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation 67:882-889